Recursion Pharmaceuticals Announces New Clinical Trial Enrollment for REC-1245 in Tumor Types with DNA Repair Vulnerabilities

Reuters
Aug 05
<a href="https://laohu8.com/S/RXRX">Recursion</a> Pharmaceuticals Announces New Clinical Trial Enrollment for REC-1245 in Tumor Types with DNA Repair Vulnerabilities

Recursion Pharmaceuticals Inc. has announced updates on its clinical programs, including the ongoing Phase 1/2 DAHLIA study for REC-1245, a potential first-in-class RBM39 degrader. This study is currently enrolling patient populations characterized by replication stress and DNA repair vulnerabilities. Additionally, Recursion has identified platinum-resistant ovarian cancer as the first combination cohort for its CDK7 inhibitor, REC-617, utilizing multi-omic and real-world patient data alongside causal AI modeling. The company reported these developments and financial results for the second quarter of 2025, highlighting their strategic use of advanced models and platform capabilities to enhance both internal and partnered programs. Results from these studies have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9506150-en) on August 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10